AptarGroup ATR
United StatesHealthcare · Medical Instruments & SuppliesUSD
167.57 USD (+39.1%)
7 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
AptarGroup, Inc. is a global provider of packaging and dispensing solutions for the pharmaceutical, consumer, and beauty sectors, with a business model based on manufacturing precision components and drug delivery systems.
Key points
from its scores- ✓Favourable backdrop8.3
- ✕Weak growth3.8
- ✕Poor share-price trend4.5
- !Somewhat demanding valuation5.2
AI analysis
bottom line, main risk, context and newsThe company has stable fundamentals but lacks clear catalysts; wait for an improvement in earnings trend or a more attractive price.
AptarGroup shows solid financial health (6.57) with moderate leverage (ND/EBITDA of 1.52) and acceptable quality (ROIC 12.17%), but its earnings growth is negative (-18.60%) and its valuation (P/E 21.74) offers no margin of safety. The dividend is sustainable with a payout of 34.12%.
The decline in earnings (-18.60%) and limited free cash flow conversion (33.31%) suggest operational pressures that could persist if margin recovery does not materialize.
Context and risks
AptarGroup operates in the medical devices and pharmaceutical sector, subject to ongoing regulatory scrutiny by the FDA and other health agencies. Although its country risk profile is moderate (United States), the nature of its business implies an inherent regulatory risk not captured by financial metrics.
Is AptarGroup stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 21% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 21.7 | 26.7 | −19% |
| EV / EBITDA | 11.2 | 14.5 | −23% |
| Price / book | 2.9 | 4.1 | −29% |
| Price / sales | 1.9 | 3.4 | −43% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.2 out of 10 (median for Healthcare: 4.7).
Average analyst target: 167.57 USD, +39.1% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 6.6 (sector 6.5), Growth 3.8 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 21.7
- Forward P/E
- 19.1
- EV / EBITDA
- 11.2
- Price / book
- 2.9
- Price / sales
- 1.9
- PEG
- 2.51
- Market cap
- 7.7B USD
- Enterprise value
- 8.9B USD
Profitability
- ROE
- 13.5%
- ROA
- 6.1%
- ROIC (approx.)
- 12.2%
- Gross margin
- 36.1%
- Operating margin
- 12.5%
- Net margin
- 9.2%
- Free cash flow
- 266.0M USD
- FCF yield
- 3.5%
- Cash conversion
- 33%
Solvency
- Total debt
- 1.4B USD
- Net debt
- 1.2B USD
- Cash
- 197.3M USD
- EBITDA
- 798.4M USD
- Net debt / EBITDA
- 1.52
- Debt / equity
- 52.78
- Current ratio
- 1.61
- Quick ratio
- 0.98
Growth
- Revenue growth
- +6.3%
- Earnings growth
- −18.6%
- EPS (TTM)
- 5.54 USD
- EPS (forward)
- 6.30 USD
Dividend
- Dividend yield
- 1.6%
- Payout
- 34.1%
Risk and market
- Beta
- 0.34
- Analyst consensus
- Strong buy (7)
- Target price
- 167.57 USD
- 52-week range
- 103.23 – 146.91
Recent news
All ATR news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about AptarGroup
Is AptarGroup stock cheap or expensive?
On P/E and EV / EBITDA, it trades 21% below the Healthcare median on average. Valuation score: 5.2 out of 10 (median for Healthcare: 4.7). Average analyst target: 167.57 USD, +39.1% versus the price. This is not investment advice.
What score does AptarGroup get on MeridIAn Screener?
It scores 5.7 out of 10, rank 1,223 of 2,130 (better than 39% of the companies analysed). Its strongest category is Risk & Context (8.3) and its weakest, Growth (3.8). Analysis of 08/10/2026.
What is AptarGroup's P/E ratio?
Its P/E is 21.7: the share price equals 21.7 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 19.1.
How much is AptarGroup worth on the stock market?
Its market capitalisation is 7.7B USD and its enterprise value, debt included, is 8.9B USD.
How much debt does AptarGroup have?
Its net debt (debt minus cash) is 1.2B USD. That is 1.52 times its EBITDA; the Healthcare median is 1.53.
Does AptarGroup pay a dividend?
Yes: its dividend yield is 1.59% and it pays out 34% of its earnings.
How has AptarGroup stock performed over the last year?
It has fallen 6.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 103.23 and 146.91 USD. Past performance does not guarantee future results.
What do analysts think of AptarGroup?
7 analysts cover it; their average recommendation is “Strong buy” and their average target is 167.57 USD (+39.1% versus the price). It is an estimate, not market data.